TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06084689
Drug: Ezabenlimab + BI907828
Normalized name: Ezabenlimab
DrugBank: Ezabenlimab (DB17483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A treatment cycle consists of 3 weeks. Both treatments will be administered on Day 1 of each cycle.
Study: NCT05395507
Drug: Recombinant Interferon Alpha
Normalized name: interferon gamma, porcine recombinant
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant Interferon Alpha, with an initial dose of 300 wu three times a week. Other interferons that have been listed can be used if Recombinant Interferon Alpha (300 wu) is not available.
Study: NCT05395507
Drug: Pegylated interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated Interferon Alfa-2b, with an initial dose of 135 ug at week 0 , and then 180 ug once a week from week 1 to week 52.
Study: NCT05688371
Drug: low dose morphine plus dexmedetomidine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Receiving 0.02 mg morphine/kg as a bolus dose + 0.2 microgram/kg dexmedetomidine
Study: NCT06251453
Drug: SGLT2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapagliflozin Empagliflzoin
Study: NCT05271292
Drug: Chiauranib
Normalized name: Chiauranib
DrugBank: Chiauranib (DB16124)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1b: Each patient will undergo both a single-dose period (6 days) and a consecutive-dose (1 cycle of 28 days) period~Phase 2: Patients will take the RP2D once daily for 28-day cycles continuously with no interruption between cycles
Study: NCT06065774
Drug: Modified Coronally Advanced Tunnel Technique with collagen matrix mucograft
Normalized name: Matrix
DrugBank: Matrix-M (DB16369)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supraperiosteal incisions was extended to the mucosal level beyond the MGJ to allow sufficient tissue mobility and release.~The tunnel was extended in all directions around the recession defect to create a sufficient pouch for connective tissue graft stabilization.~The interdental papilla tunneling adjacent to the defect was a critical step for technique success.~Then perfect root planning was performed at the denuded root surface to remove the necrotic cementum at the accessible recession defect.~Subsequently palatal anesthesia was given to harvest palatal SCTG using deepitheliailized free gingival graft (FGG) technique.~collagen matrix was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material \[Vicryl suture\], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene.
Study: NCT00006332
Drug: Tetrathiomolybdate
Normalized name: Tetrathiomolybdate
DrugBank: Tetrathiomolybdate (DB05088)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04783415
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04783415
Drug: Umbralisib
Normalized name: Umbralisib
DrugBank: Umbralisib (DB14989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT06649851
Drug: Granulocyte Colony Stimulating Factor (G-CSF)
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneously injected study drug; standard target dose of 5-7 µg/kg/d.
Study: NCT06682117
Drug: DC Vaccine
Normalized name: Recombinant chimeric COVID-19 DC vaccine
DrugBank: Dendritic cells vaccine (DB15803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Neo-DC vaccine infusion either by dose 1 (1×10\^7 cells/time) or dose 2 (5×10\^7 cells/time) every 7 days, four cell infusions are one treatment cycle.~The dose limited toxity observation time is within 28 days after the first Neo-DC vaccine infusion.~If the efficacy is evaluated as clinical benefit (CR/PR/SD) or immune unconfirmed progress ( iUPD), treatment cycle can be continued until the completion of four Neo-DC vaccine administrations or disease progression (iCPD by iRECIST) or start new anti-tumor treatment or stop treatment by other reasons.
Study: NCT06710977
Drug: Safety of intracameral levofloxacin in cataract surgery
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracameral levofloxacin (0.1ml/0.5mg)
Study: NCT06710977
Drug: Use of intracameral cefazolin in cataract surgery
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracameral cefazolin (0.1ml/1mg)
Study: NCT06712472
Drug: Olaparib (300 mg BID)
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 300mg Bid during one year.
Study: NCT05904106
Drug: Venetoclax plus Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction cycle 1:~100 mg venetoclax p.o. on day 1; 200 mg venetoclax p.o. on day 2; 400 mg venetoclax p.o. on days 3-28; 75 mg/m\^2 azacitidine s.c. on days 1-7~Induction cycles 2-3:~400 mg venetoclax p.o. on days 1-28; 75 mg/m\^2 azacitidine s.c. on days 1-7~Postremission cycles 1-9:~400 mg venetoclax p.o. on days 1-28; 75 mg/m\^2 azacitidine s.c. on days 1-7
Study: NCT05904106
Drug: standard of care chemotherapy plus gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Induction cycle 1:~200 mg/m\^2 cytarabine cont inf i.v. on days 1-7; 60 mg/m\^2 daunorubicin i.v. on days 3-5; 3 mg/m\^2 (max 1 vial) gemtuzumab ozogamicin i.v. on days 1+4+7~Induction cycle 2 (patients not in remission, moderate or non-responders):~3000/1000 mg/m\^2 cytarabine i.v. BID on days 1-3; 10 mg/m\^2 mitoxantrone i.v. on days 3-5~Postremission cycles 1-3:~3000/1000 mg/m\^2 cytarabine i.v. BID on days 1-3
Study: NCT05375916
Drug: Hydromorphone
Normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release hydromorphone is a long-acting preparation opioid
Study: NCT04869943
Drug: Enobosarm
Normalized name: enobosarm
DrugBank: Enobosarm (DB12078)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Enobosarm 9mg per day
Study: NCT04869943
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator (SERM)
Study: NCT03185000
Drug: TR004 (Treg immunotherapy)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered Intravenously (IV)
Study: NCT04774406
Drug: olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients treated at least with 1 PARPi (alone or in combination)
Study: NCT05664386
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: propofol 2～2.5mg/kg was used for anesthesia induction. propofol is an intravenous sedative-hypnotic and a short-acting GABAA receptor agonist. It activates GABAergic neurons by enhancing chloride ion influx. It is used for anesthesia of induction and maintenance.
Study: NCT05664386
Drug: ciprofol
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofol 0.4～0.5mg/kg was used for anesthesia induction. Ciprofol is an intravenous sedative-hypnotic and a short-acting GABAA receptor agonist. It activates GABAergic neurons by enhancing chloride ion influx. It is used for anesthetic induction and maintenance agents include rapid induction of general anesthesia, rapid recovery of consciousness, minimal residual effects on the central nervous system and less injection pain.
Study: NCT05500937
Drug: UDCA
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA vs. placebo together with statin in ASCVD patients
Study: NCT06311604
Drug: Isoflurane
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inclusions will have 4 phases according to gradual increased doses of isoflurane:~Phase 1: Inclusion of 3 patients with 0.3 MAC isoflurane. In the absence of an increase of ICP \> 20% from baseline, inhaled sedation is maintained for 24 hours until the primary endpoint is assessed. If there one patient who does not tolerate this threshold, three additional patients will be included in this phase. A maximum of one treatment failure (see definition below) is tolerated in the phase 1~Phase 2: Inclusion of 3 additional patients with isoflurane dosage of 0.5 MAC under the same conditions as phase 1.~Phase 3: Inclusion of 3 additional patients with isoflurane dosage of 0.7 MAC under the same conditions as phases 1 and 2.~Phase 4: Inclusion of 12-15 additional patients will be included at the 0.7 MAC dose, to have 18 patients exposed to 0.7 MAC isoflurane.
Study: NCT05975151
Drug: Pseudomonas aeruginosa
Normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 63 subjects with intermediate and high risk NMIBC who were scheduled for transurethral resection of bladder tumor (TURBT) from March 2023 in three centers were enrolled in this study. The enrolled patients received submucosal injection of 1U of Pseudomonas aeruginosa injection and bladder irrigation with chemotherapy drugs (gemcitabine, mitomycin C, epirubicin or pirarubicin) immediately after TURBT. After urine was cleared, a sterile urinary catheter was placed, and 10U of Pseudomonas aeruginosa injection and 40ml of normal saline were injected. The perfusion solution was kept for 1 hour, and the position was changed every 20 minutes. The treatment was given once within 24 hours after operation, then once a week for 12 weeks, and then once a month for 12 months in total. Patients were followed up every 3 months after surgery. The last follow-up was completed in February 2025
Study: NCT05627596
Drug: Nicotine Patch, 14 Mg/24 Hr Transdermal Film, Extended Release
Normalized name: Nicotine Patch, 14 mg/24 hr transdermal film, extended release
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14 mg transdermal nicotine patch
Study: NCT05627596
Drug: Nicotine lozenge
Normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4mg nicotine lozenge
Study: NCT04429880
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin given by intravenous route
Study: NCT04910646
Drug: orange peel fermentation
Normalized name: orange peel extract
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To evaluate whether the fermented orange peel enzyme has the effect of reducing body fat.
Study: NCT05648734
Drug: Corticosteroids alone
Normalized name: abiraterone and corticosteroids
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (≥ 20 mg prednisolone or its equivalent for ≥ 10 days after hospital discharge)
Study: NCT05648734
Drug: Corticosteroids + Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (≥ 20 mg prednisolone or its equivalent for ≥ 10 days) + Colchicine (1 mg/day for ≥ 10 days)
Study: NCT05648734
Drug: Corticosteroids + Pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: (≥ 20 mg prednisolone or its equivalent for ≥ 10 days) + Pirfenidone (267 mg TID for ≥ 14 days)
Study: NCT05648734
Drug: Corticosteroids + Colchicine + Pirfenidone for ≥ 14 days
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (≥ 20 mg prednisolone or its equivalent for ≥ 10 days) + Colchicine (1 mg/day for ≥ 10 days) + Pirfenidone (267 mg TID for ≥ 14 days)
Study: NCT05811481
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib alone
Study: NCT05281965
Drug: Retinoic acid
Normalized name: Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Retinoic acid oral
Study: NCT05822453
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (1000 mg/m2) will be administered by IV infusion on Day 1and Day 8 of each 21-day cycle
Study: NCT05822453
Drug: S1
Normalized name: LS11
DrugBank: LS11 (DB05918)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S1 (60 mg/day if body surface area \< 1.25 m2, 80 mg/day if body surface area = 1.25\~1.50 m2) will be administered by PO on Day 1 \~ 14 of each 21-day cycle
Study: NCT05822453
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab (200 mg) will be administered by IV infusion on Day 1 of each 21-day cycle
Study: NCT05614037
Drug: Felodipine sustained release tablets (trade name: plendil®)
Normalized name: felodipine Extended Release Oral Tablet [Plendil]
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reference preparation (R) : Felodipine sustained release tablets (trade name: plendil ®) Specification: 5 mg Batch number: 2204 a11 Content: 99.1% Valid until March 2025 Storage conditions: below 25℃ Manufacturer: AstraZeneca AB Supplier: Overseas Pharmaceuticals, Ltd. Usage: Oral, 1 tablet at a time, once a day. Take it before bed and swallow it with water. Do not break, press or chew the pill.
Study: NCT05737186
Drug: SGLT-2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dapagliflozin
Study: NCT06094920
Drug: Empagliflozin 10 MG
Normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral administration
Study: NCT06094920
Drug: Finerenone
Normalized name: Finerenone
DrugBank: Finerenone (DB16165)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral administration.~Finerenone treatment may be initiated if serum potassium levels are ≤5.0 mmol/L. Conversely, if serum potassium levels are \>5.0 mmol/L, the initiation of finerenone treatment should be avoided. In such cases, a second serum potassium measurement will be performed two days later. If serum potassium levels are ≤5.0 mmol/L, these patients can still be considered for inclusion. However, if serum potassium levels are \>5.0 mmol/L again, these patients will be excluded, and an assessment of the underlying cause(s) of hyperkalaemia will be conducted.~The recommended initial dose of finerenone is determined based on eGFR, which will be assessed prior to the commencement of the trial. If eGFR is ≥60 mL/min/1.73m2, the dose will be set at 20 mg once daily. If eGFR is ≥25 to \<60, the dose will be set at 10 mg once daily. Participants with an eGFR \<25 are not advised to undergo finerenone treatment and will be excluded from the study.
Study: NCT04879368
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral multi-targeted tyrosine kinase inhibitor (TKI) which targets angiogenic (VEGF, TIE-2), stromal (PDGF-β), and oncogenic (RAF, RET and KIT) receptor tyrosine kinases
Study: NCT04879368
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel is taxane-derivative chemotherapy drug, used in the treatment of early, locally advanced and metastatic breast cancer. It is an anti-microtubule agent. Other uses are in the treatment of non-small cell lung cancer, advanced stomach cancer, head and neck cancers, soft tissue sarcoma, ovarian cancer, metastatic prostate cancer, etc.~microtubules, and simultaneously promotes assembly and inhibits disassembly of them
Study: NCT04879368
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel is one of several cytoskeletal drugs that target tubulin. Paclitaxel-treated cells have defects in mitotic spindle assembly, chromosome segregation, and cell division. Unlike other tubulin-targeting drugs, such as colchicine, that inhibit microtubule assembly, paclitaxel stabilizes the microtubule polymer and protects it from disassembly. Chromosomes are thus unable to achieve a metaphase spindle configuration. This blocks the progression of mitosis and prolonged activation of the mitotic checkpoint triggers apoptosis or reversion to the G0-phase of the cell cycle without cell division
Study: NCT04879368
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Camptothecin, one of the four major structural classifications of plant-derived anti-cancerous compounds, is a cytotoxic alkaloid which consists of a pentacyclic ring structure containing a pyrrole (3, 4 β) quinoline moiety, an S-configured lactone form, and a carboxylate form. Irinotecan is activated by hydrolysis to SN-38, an inhibitor of topoisomerase I. This is then inactivated by glucuronidation by uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1). The inhibition of topoisomerase I by the active metabolite SN-38 eventually leads to inhibition of both DNA replication and transcription.
Study: NCT05614037
Drug: Felodipine Controlled Release Tablets
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test preparation (T) :Felodipine Controlled Release Tablets Specification: 5 mg Batch number: 22090301 Content: 100.8% Valid until: September 2024 Storage conditions: sealed, room temperature (10\~30℃) Manufacturer: Overseas Pharmaceuticals, Ltd. Supplier: Overseas Pharmaceuticals, Ltd. Usage: Oral, 1 tablet at a time, once a day. Take it before bed and swallow it with water. Do not break, press or chew the pill.
Study: NCT06165939
Drug: hydrodilation with Normal saline
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The second round of ultrasound-guided shoulder joint injection is performed at the fourth week during the follow-up period and the injectate is Normal saline (2 ml 2% Xylocaine + 18 ml normal saline, totaling 20 ml).
Study: NCT05216575
Drug: Administration of Almitrine
Normalized name: almitrine
DrugBank: Almitrine (DB01430)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of Almitrine (intravenous bolus of 0.5 mg/kg over 30 minutes followed by a continuous perfusion of 16 mg/kg/min in responders)
Study: NCT05158998
Drug: propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For patients in the propofol group, anaesthesia will be maintained with propofol infusion(target controlled infusion), of which the target concentration will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be maintained with remifentanil(0.1-0.5ug/(kg.min)), muscle relaxation will be maintained with atracurium(10ug/(kg.min)).Propofol infusion will be stopped at the end of surgery.
Study: NCT05158998
Drug: sevoflurane inhalation
Normalized name: Sevoflurane Inhalation Liquid
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For patients in the sevoflurane group, anaesthesia will be maintained with sevoflurane inhalation, of which the concentration will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be maintained with remifentanil(0.1-0.5ug/(kg.min)), muscle relaxation will be maintained with atracurium(10ug/(kg.min)). Sevoflurane inhalation will be stopped at the end of surgery.
Study: NCT00120939
Drug: Motexafin Gadolinium
Normalized name: Motexafin gadolinium
DrugBank: Motexafin gadolinium (DB05428)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05662813
Drug: Almonertinib
Normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almonertinib 110mg p.o qd. Patients receive Almonertinib treatment until disease progression, unacceptable toxicity or other discontinuation criteria.
Study: NCT05238597
Drug: Active Comparator
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Comparator
Study: NCT05895773
Drug: Povidone-Iodine
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone Iodine 0.5% plus glycyrrhizin acid 2.5 mg/ml as a nasal and an oropharyngeal spray (mint flavored) will be applied 4 times per day.
Study: NCT05304520
Drug: Natalizumab
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT05660850
Drug: GDC-6599
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GDC-6599 will be administered Days 1- 14 and on Days 29-42 as film-coated tablets
Study: NCT05207787
Drug: HS-10365
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or multiple dose(s) of HS-10365 daily or twice every day. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and/or unequivocal disease progression.
Study: NCT04896255
Drug: nucleos(t)ide
Normalized name: T-5224
DrugBank: 6-hydroxy-1,6-dihydro purine nucleoside (DB03015)
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon alpha based regimen or nucleos(t)ide alone are decided by patients' doctors according to their conditions, instead of extra interventions brought by the study
Study: NCT05192642
Drug: Larotrectinib(Vitrakvi, BAY2757556)
Normalized name: larotrectinib 100 MG [Vitrakvi]
DrugBank: Larotrectinib (DB14723)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Clinical trials
Study: NCT05601336
Drug: Dapagliflozin 5 MG
Normalized name: dapagliflozin 5 MG
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SGLT2 inhibitor
Study: NCT05601336
Drug: Metformin Hydrochloride 1000 MG
Normalized name: metformin hydrochloride 1000 MG
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: metformin
Study: NCT05601336
Drug: Dapagliflozin/Metformin
Normalized name: DAPAGLIFLOZIN/METFORMIN
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: SGLT2 inhibitor and metformin HCl extended-release
Study: NCT05161390
Drug: LM-302 Injection
Normalized name: LM-030
DrugBank: LM-030 (DB18283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LM-302 Injection with dose escalation stage of different dose levels, as well as dose expansion stage with recommended dose level from dose escalation stage.
Study: NCT04497584
Drug: Afatinib + Prednisone
Normalized name: Afatinib
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib (40mg) will be taken by mouth daily starting on Cycle 1, Day -7. Prednisone (40mg) will be taken by mouth daily starting on Cycle 1, Day 1.